Tenaya Therapeutics Presents New Clinical And Preclinical Data From HDAC6 Inhibitor Program TN-301 For The Potential Treatment Of Heart Failure With Preserved Ejection Fraction At The 2023 HFSA Annual Scientific Meeting
Portfolio Pulse from Benzinga Newsdesk
Tenaya Therapeutics presented new clinical and preclinical data from its HDAC6 inhibitor program TN-301 at the 2023 HFSA Annual Scientific Meeting. The data shows TN-301's tolerability, potential for once daily dosing, target engagement, and selectivity for HDAC6 in a Phase 1 clinical trial. Additionally, a combination of Tenaya's HDAC6 inhibitors with Empagliflozin showed additive benefits in a preclinical HFpEF model.
October 09, 2023 | 12:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tenaya Therapeutics' HDAC6 inhibitor program TN-301 shows promising results in Phase 1 clinical trial and preclinical HFpEF model.
The positive results from the Phase 1 clinical trial and preclinical HFpEF model of Tenaya Therapeutics' HDAC6 inhibitor program TN-301 could potentially increase investor confidence in the company and its products, leading to a potential increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100